Biopharmaceuticals
Arrowhead Pharmaceuticals is a commercial-stage biopharmaceutical company that develops RNA interference (RNAi) therapies to treat intractable genetic diseases by silencing disease-causing genes. The company leverages a broad portfolio of RNA chemistries and efficient delivery modes to trigger the natural gene silencing mechanism in living cells, enabling treatment of conditions not addressable by traditional small molecules and biologics. Arrowhead's clinical pipeline includes therapies targeting liver and lung diseases, with its first commercial asset, Redemplo (plozasiran), approved in November 2025 for treating Familial Chylomicronemia Syndrome. The company operates research and development teams across multiple locations and maintains a state-of-the-art manufacturing facility, positioning itself as a leader in bringing RNAi therapeutics beyond liver-targeted applications.
Industry
Biopharmaceuticals
Remote Policy
Office-first with remote options
Beta · Sourced from candidate reports
Be the first to share your experience with Arrowhead Pharmaceuticals.
Your reply helps other candidates know what to expect.
